Organon & Co. (NYSE:OGN) Stock Position Cut by Clean Yield Group

Clean Yield Group reduced its holdings in shares of Organon & Co. (NYSE:OGN - Free Report) by 77.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,534 shares of the company's stock after selling 87,164 shares during the quarter. Clean Yield Group's holdings in Organon & Co. were worth $380,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Millstone Evans Group LLC acquired a new position in shares of Organon & Co. during the 4th quarter valued at $29,000. Larson Financial Group LLC boosted its position in shares of Organon & Co. by 345.4% in the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company's stock worth $33,000 after buying an additional 1,734 shares during the period. Riverview Trust Co boosted its position in shares of Organon & Co. by 117.7% in the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company's stock worth $36,000 after buying an additional 1,292 shares during the period. GeoWealth Management LLC acquired a new stake in shares of Organon & Co. in the fourth quarter valued at about $41,000. Finally, Jones Financial Companies Lllp raised its holdings in shares of Organon & Co. by 1,795.8% during the 4th quarter. Jones Financial Companies Lllp now owns 4,550 shares of the company's stock valued at $68,000 after buying an additional 4,310 shares during the period. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Organon & Co. Stock Performance

NYSE:OGN traded up $0.20 during trading hours on Monday, reaching $9.76. 3,890,773 shares of the stock were exchanged, compared to its average volume of 3,391,094. The stock has a market capitalization of $2.54 billion, a P/E ratio of 2.93, a P/E/G ratio of 0.90 and a beta of 0.58. The firm has a 50 day simple moving average of $10.41 and a 200-day simple moving average of $13.60. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. Organon & Co. has a 52 week low of $8.01 and a 52 week high of $23.10.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $1.02 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $0.13. The firm had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.53 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The firm's revenue was down 6.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.22 earnings per share. As a group, sell-side analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Stockholders of record on Monday, May 12th will be given a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.82%. The ex-dividend date of this dividend is Monday, May 12th. Organon & Co.'s payout ratio is 2.78%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on OGN shares. Barclays decreased their price target on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a report on Friday, February 14th. BNP Paribas upgraded shares of Organon & Co. to a "strong-buy" rating in a research note on Thursday, May 22nd. Evercore ISI downgraded shares of Organon & Co. from an "outperform" rating to an "inline" rating in a research note on Friday, May 2nd. Morgan Stanley decreased their price objective on shares of Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. Finally, Piper Sandler dropped their target price on Organon & Co. from $24.00 to $18.00 and set an "overweight" rating on the stock in a research report on Thursday, May 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $18.00.

Insider Buying and Selling

In other news, VP Daniel Karp acquired 3,500 shares of the business's stock in a transaction that occurred on Tuesday, May 6th. The shares were purchased at an average cost of $8.24 per share, for a total transaction of $28,840.00. Following the transaction, the vice president now directly owns 46,669 shares in the company, valued at $384,552.56. This trade represents a 8.11% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin Ali purchased 34,000 shares of the company's stock in a transaction on Monday, May 5th. The stock was purchased at an average price of $8.80 per share, for a total transaction of $299,200.00. Following the purchase, the chief executive officer now directly owns 282,731 shares of the company's stock, valued at $2,488,032.80. This trade represents a 13.67% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 102,345 shares of company stock valued at $902,430. Insiders own 1.96% of the company's stock.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.